Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Preparation and testing of a Vi conjugate vaccine using pneumococcal surface protein A (PspA) from Streptococcus pneumoniae as the carrier protein.
[typhoid]
In
the
current
study
pneumococcal
surface
protein
A
(
PspA
)
was
conjugated
to
Vi
capsular
polysaccharide
from
Salmonella
Typhi
to
make
available
a
vaccine
against
typhoid
fever
that
has
the
potential
to
also
provide
broad
protection
from
Streptococcus
pneumoniae
.
High
yielding
production
processes
were
developed
for
the
purification
of
PspAs
from
families
1
and
2
.
The
purified
PspAs
were
conjugated
to
Vi
with
high
recovery
of
both
Vi
and
PspA
.
The
processes
developed
especially
for
PspA
family
2
could
readily
be
adapted
for
large
scale
production
under
cGMP
conditions
.
Previously
we
have
shown
that
conjugation
of
diphtheria
toxoid
(
DT
)
to
Vi
polysaccharide
improves
the
immune
response
to
Vi
but
can
also
enhance
the
response
to
DT
.
In
this
study
it
was
shown
that
conjugation
of
PspA
to
Vi
enhanced
the
anti-
PspA
response
and
that
PspA
was
a
suitable
carrier
protein
as
demonstrated
by
the
characteristics
of
a
T
-
cell
dependent
response
to
the
Vi
.
We
propose
that
a
bivalent
vaccine
consisting
of
PspA
from
families
1
and
2
bound
to
Vi
polysaccharide
would
protect
against
typhoid
fever
and
has
the
potential
to
also
protect
against
pneumococcal
disease
and
should
be
considered
for
use
in
developing
countries
.
Diseases
Validation
Diseases presenting
"high recovery"
symptom
typhoid
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom